The present invention provides an inhalation-type pharmaceutical composition for alzheimers disease comprising a first gas and a vaporized pharmaceutical liquid. The first gas comprises hydrogen. The hydrogen has a gas volume concentration between 2% and 96% in the inhalation-type pharmaceutical composition. The vaporized pharmaceutical liquid comprises at least one selected from the group consisting of rivastigmine hydrogen tartrate, donepezil hydrochloride, galantamine hydrobromide, and memantine hydrochloride. The inhalation-type pharmaceutical composition of the present invention can remove reactive oxygen, and the vaporized pharmaceutical liquid can improve absorbability in the present invention. At the same time, because the use of the small amount of the vaporized pharmaceutical liquid indirectly reduce the side effects of human.
